Voriconazole steady -state plasma trough concentrations in patients with cytochrome 2C19 polymorphism:A systematic review
10.13699/j.cnki.1001-6821.2016.03.022
- VernacularTitle:不同细胞色素 P4502 C19基因型患者伏立康唑稳态血药谷浓度的系统评价
- Author:
Ken CHEN
1
;
Xiao-Fei LI
;
Hui-Lin TANG
;
Suo-Di ZHAI
Author Information
1. 北京大学 第三医院 药剂科
- Keywords:
voriconazole;
steady -state plasma trough concentration;
cytochrome 2 C19;
single-arm meta analysis
- From:
The Chinese Journal of Clinical Pharmacology
2016;(3):264-266
- CountryChina
- Language:Chinese
-
Abstract:
Objective To estimate voriconazole steady -state plasma trough concentrations in cytochrome 2 C19 ( CYP2 C19 ) poor metabolizers (PMs), heterozygous extensive metabolizers (HEMs) and extensive me-tabolizers ( EMs ) when using standard dosing regimen.Methods PubMed , EmBase , the Cochrane Library , Clinicaltriasl.gov and three Chinese databases ( CNKI, CBM, and WanFang ) were searched through March 2015.Clinical trials and observational studies reporting voricon-azole steady-state plasma trough concentrations of PMs , HEMs, or EMs were included.Studies with healthy subjects or patients using non -standard voriconazole dosing regimen were excluded.Single-arm meta-analysis was performed using the random effect model.Estimated steady-state plasma trough concentrations with 95% confidence intervals ( 95%CIs ) were calculated for PMs , HEMs and EMs respectively.Results Five observational studies were included in the single -arm meta analysis.The sample sizes of PMs , HEMs and EMs were 39 , 143 and 170 respectively.Calculated voriconazole steady -state plasma trough concentrations for PMs , HEMs and EMs were 4.21 , 2.47 , 2.00μg· mL-1 respectively.Conclusion It is unnecessary to adjust initial voriconazole dosing regimen by routine CYP 2 C19 genotype test.
